MeSH term | MeSH ID | Detail |
---|---|---|
Adenocarcinoma | D000230 | 166 associated lipids |
Lung Neoplasms | D008175 | 171 associated lipids |
Body Weight | D001835 | 333 associated lipids |
Tacrolimus is a lipid of Polyketides (PK) class. Tacrolimus is associated with abnormalities such as Renal glomerular disease. The involved functions are known as inhibitors, Fungicidal activity, Metabolic Inhibition, Excretory function and Dephosphorylation. Tacrolimus often locates in Hepatic, Mitochondrial matrix and Inner mitochondrial membrane. The associated genes with Tacrolimus are RHOA gene and BGN gene.
To understand associated biological information of tacrolimus, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.
tacrolimus is suspected in Renal glomerular disease, Candidiasis, Mycoses, PARKINSON DISEASE, LATE-ONSET, Morphologically altered structure, Skin Diseases, Infectious and other diseases in descending order of the highest number of associated sentences.
Disease | Cross reference | Weighted score | Related literature |
---|
We collected disease MeSH terms mapped to the references associated with tacrolimus
There are no associated biomedical information in the current reference collection.
Associated locations are in red color. Not associated locations are in black.
Location | Cross reference | Weighted score | Related literatures |
---|
Function | Cross reference | Weighted score | Related literatures |
---|
Lipid concept | Cross reference | Weighted score | Related literatures |
---|
Gene | Cross reference | Weighted score | Related literatures |
---|
There are no associated biomedical information in the current reference collection.
Authors | Title | Published | Journal | PubMed Link |
---|---|---|---|---|
Wiebe K et al. | FK506 rescue therapy in lung transplantation. | 1998 | Transplant. Proc. | pmid:9636613 |
Lipson DA et al. | Conversion to tacrolimus (FK506) from cyclosporine after orthotopic lung transplantation. | 1998 | Transplant. Proc. | pmid:9636612 |
McAlister VC et al. | Cost of liver transplantation using tacrolimus. | 1998 | Transplant. Proc. | pmid:9636611 |
Mueller AR et al. | Influence of immunosuppression on patient outcome after liver transplantation. | 1998 | Transplant. Proc. | pmid:9636608 |
Maggard M et al. | Incidence of acute rejection in African-American liver transplant recipients. | 1998 | Transplant. Proc. | pmid:9636607 |
Charco R et al. | Hypercholesterolemia in long-term survivors of liver transplantation: a comparison between cyclosporine and FK 506. | 1998 | Transplant. Proc. | pmid:9636605 |
Nakamura M et al. | Clinical and radiological features of two cases of tacrolimus-related posterior leukoencephalopathy in living related liver transplantation. | 1998 | Transplant. Proc. | pmid:9636600 |
Ghobrial RM et al. | Retransplantation for recurrent hepatitis C following tacrolimus or cyclosporine immunosuppression. | 1998 | Transplant. Proc. | pmid:9636597 |
Platz KP et al. | Indications for mycophenolate mofetil therapy in hepatitis C-patients undergoing liver transplantation. | 1998 | Transplant. Proc. | pmid:9636596 |
Lang M et al. | Impact of immunosuppression in liver transplantation across a positive crossmatch. | 1998 | Transplant. Proc. | pmid:9636595 |
Mueller AR et al. | Does initial graft function influence the outcome after liver transplantation? | 1998 | Transplant. Proc. | pmid:9636594 |
Cantarovich M et al. | Optimal time points for the prediction of the area-under-the-curve in liver transplant patients receiving tacrolimus. | 1998 | Transplant. Proc. | pmid:9636592 |
Bekersky I et al. | Bioequivalence of a new strength tacrolimus capsule under development. | 1998 | Transplant. Proc. | pmid:9636591 |
Liu WT et al. | In vitro generation of tacrolimus metabolites and their detection in whole blood. | 1998 | Transplant. Proc. | pmid:9636590 |
Steinmueller T et al. | Effect of CsA versus FK 506 on insulin sensitivity and insulin response using a modeling technique. | 1998 | Transplant. Proc. | pmid:9636589 |
Klupp J et al. | Risk and benefit of antibody induction therapy in combination with tacrolimus immunosuppression after liver transplantation. | 1998 | Transplant. Proc. | pmid:9636585 |
Abe M et al. | Successful prednisone withdrawal after living-related liver transplantation. | 1998 | Transplant. Proc. | pmid:9636584 |
Langrehr JM et al. | Comparison of quadruple induction including ATG or IL-2R antibody with FK506-based therapy after liver transplantation. | 1998 | Transplant. Proc. | pmid:9636583 |
Bilbao I et al. | Experience with neoral cyclosporine through the oral route in liver transplantation. | 1998 | Transplant. Proc. | pmid:9636580 |
Pratschke J et al. | Treatment of cyclosporine-related adverse effects by conversion to tacrolimus after liver transplantation: long-term results. | 1998 | Transplant. Proc. | pmid:9636575 |